

## Drug Monograph

Drug/Drug **Dexycu™ (dexamethasone) 9% for intraocular**  
 Class: **administration/ Ophthalmic “Soft” Steroids**  
 Prepared for: MO HealthNet  
 Prepared by: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Intraocular suspension: 9% equivalent to dexamethasone 103.4 mg/mL in a single-dose vial provided in a kit

**Manufacturer:** Icon Bioscience, Inc. Sunnyvale, CA 94089

**Indications:** Dexycu is a corticosteroid indicated for the treatment of postoperative inflammation.

**Costs:** \$595 per injection of Dexycu. Wholesale Acquisition Cost

**Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Fiscal Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Under Solicitation  
 Appropriate Indications  No PA Required

Prepared By: Jennifer Anderson PharmD  
 Date: March 23, 2019